✦ LIBER ✦

Chemotherapy as primary treatment for brain metastases from breast cancer: analysis of 115 one-year survivors

✍ Scribed by Willem Boogerd, Femke Groenveld, Sabine Linn, Joke W. Baars, Dieta Brandsma, Harm van Tinteren

Book ID: 113043184
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 196 KB
Volume: 138
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-012-1218-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination chemotherapy as primary trea

Combination chemotherapy as primary treatment of brain metastases from small cell lung cancer (SCLC)

📂 Article 📅 1988 🏛 Elsevier Science ⚖ 124 KB

CAN1: COST-EFFECTIVENESS ANALYSIS OF HIG

CAN1: COST-EFFECTIVENESS ANALYSIS OF HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY TREATMENT FOR METASTATIC BREAST CANCER

✍ S Trippoli; A Messori 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

Treatment outcomes and prognostic factor

Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis

✍ Niikura, Naoki; Hayashi, Naoki; Masuda, Norikazu; Takashima, Seiki; Nakamura, Ri 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 587 KB

Evaluation of the worth of Corynebacteri

Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight-year results from the national surgical adjuvant breast and bowel project B-10

✍ Bernard Fisher; Ann Brown; Norman Wolmark; Edwin R. Fisher; Carol Redmond; D. La 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

During the 1970s, information obtained from animal tumor models and from patients with a spectrum of solid tumors indicated the worth of a variety of immunostimulating agents. These findings provided a biological and clinical rationale for conducting randomized trials to evaluate the worth of those

24 Zoledronic acid (ZOL) as add-on thera

24 Zoledronic acid (ZOL) as add-on therapy in patients with tumour residuals after neoadjuvant chemotherapy for primary breast cancer – first interim safety analysis of the NATAN study (GBG 36)

✍ G. von Minckwitz; M.D. Zahm; H. Eidtmann; H. Tesch; A. du Bois; K. Schwedler; J. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB